Which second‑generation antipsychotics (SGAs) are associated with minimal weight gain?

Second-Generation Antipsychotics with Minimal Weight Gain

Lurasidone and ziprasidone are the most weight-neutral second-generation antipsychotics, with aripiprazole demonstrating a lower risk for weight gain as well 1.

Weight-Neutral SGAs (Ranked by Evidence)

First-Tier: Most Weight-Neutral

• Lurasidone: Appears to be among the most weight-neutral in the class 1
• Ziprasidone: Consistently demonstrates minimal weight gain, with only 7% of patients experiencing >7% weight gain from baseline (compared to 30% with olanzapine) 2
  • Produces significantly less weight gain than olanzapine (mean difference -3.82 kg), quetiapine, and risperidone 2
  • Associated with less cholesterol increase than olanzapine, quetiapine, and risperidone 2

Second-Tier: Lower Risk

• Aripiprazole: Generally demonstrates lower risk for weight gain compared to other SGAs 1
  • In pediatric populations with autism, weight gain ranged from 0 to 4.4 kg (compared to 3.8-16.2 kg with olanzapine) 2
  • Switching to aripiprazole resulted in significant weight loss (-5.52 kg) and improved fasting glucose and triglycerides 3

SGAs Consistently Associated with Weight Gain (Avoid When Weight is a Concern)

The following should be avoided when weight gain is a clinical concern:

• Olanzapine: Highest weight gain potential (30% of patients gain >7% body weight) 2
• Clozapine: Severe weight gain continuing up to 46 months, with 37% increased incidence of type 2 diabetes 2
• Quetiapine: 16% of patients experience >7% weight gain 2
• Risperidone: 14% of patients experience >7% weight gain 2

Clinical Decision-Making Algorithm

When prescribing SGAs with weight concerns:

1. First choice: Lurasidone or ziprasidone for weight-neutral options
2. Second choice: Aripiprazole if first-tier agents are not suitable
3. If already on high-risk SGA: Consider switching from olanzapine to ziprasidone, which results in weight loss and improved glucose tolerance and lipid profiles 1, 2

Important Caveats

Antipsychotic-Naive Patients

Weight gain is significantly more pronounced in antipsychotic-naive patients compared to those switching medications 4, 5. This makes initial agent selection particularly critical.

Duration of Treatment

Weight gain increases with longer duration of antipsychotic use 4, 5. The plateau effect varies by agent—some continue increasing weight gain at higher doses while others plateau 6.

Switching Considerations

The rationale for switching antipsychotics to achieve weight reduction may be overrated 4. However, switching to aripiprazole or ziprasidone can improve weight and cardiometabolic outcomes without increased dropout rates or worsening psychosis 3. Both the pre-switch and post-switch antipsychotic weight gain potential must be considered.

Metabolic Monitoring

Before starting any antipsychotic, obtain: BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function, renal function, and ECG 7. Check BMI and blood pressure weekly for 6 weeks, then at 3 months and annually thereafter 7.

Adjunctive Interventions

For patients requiring olanzapine or clozapine (the highest weight gain agents), adjunctive metformin should be offered at initiation, starting at 500 mg daily and titrating to 1 g twice daily 7.